Kodiak Sciences to present results from wet AMD drug study

Kodiak Sciences Inc., a biotechnology company focused on retinal diseases, announced on September 25, 2026, that it will report topline results from the DAYBREAK Phase 3 study. The study evaluates Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) for the treatment of patients with wet age-related macular degeneration (AMD).

The results are scheduled to be presented during a webcast on September 28, 2026. This study is a critical step in the company's efforts to bring new therapies to market for conditions that threaten vision, addressing a significant unmet medical need.

Wet AMD affects a substantial patient population, and effective treatments are in high demand. Kodiak Sciences is targeting the large, $15 billion global anti-VEGF market for retinal vascular diseases with its drug candidates.

Kodiak Sciences has a pipeline of three late-stage clinical programs. The company aims to develop and commercialize next-generation therapies for retinal diseases, with the goal of preventing and treating the leading causes of blindness worldwide.